- Home
- HURA vs CRDL Comparison
HURA vs CRDL Comparison
Compare HURA & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- CRDL
- Stock Information
- Founded
- HURA 2009
- CRDL 2017
- Country
- HURA United States
- CRDL Canada
- Employees
- HURA N/A
- CRDL N/A
- Industry
- HURA
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HURA
- CRDL Health Care
- Exchange
- HURA Nasdaq
- CRDL Nasdaq
- Market Cap
- HURA 103.3M
- CRDL 112.4M
- IPO Year
- HURA N/A
- CRDL N/A
- Fundamental
- Price
- HURA $2.33
- CRDL $1.33
- Analyst Decision
- HURA Strong Buy
- CRDL Strong Buy
- Analyst Count
- HURA 2
- CRDL 2
- Target Price
- HURA $11.50
- CRDL $9.00
- AVG Volume (30 Days)
- HURA 475.4K
- CRDL 200.3K
- Earning Date
- HURA 08-15-2025
- CRDL 08-11-2025
- Dividend Yield
- HURA N/A
- CRDL N/A
- EPS Growth
- HURA N/A
- CRDL N/A
- EPS
- HURA N/A
- CRDL N/A
- Revenue
- HURA N/A
- CRDL N/A
- Revenue This Year
- HURA N/A
- CRDL N/A
- Revenue Next Year
- HURA $69.15
- CRDL N/A
- P/E Ratio
- HURA N/A
- CRDL N/A
- Revenue Growth
- HURA N/A
- CRDL N/A
- 52 Week Low
- HURA $1.80
- CRDL $0.77
- 52 Week High
- HURA $10.49
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- HURA N/A
- CRDL 48.40
- Support Level
- HURA N/A
- CRDL $1.28
- Resistance Level
- HURA N/A
- CRDL $1.42
- Average True Range (ATR)
- HURA 0.00
- CRDL 0.10
- MACD
- HURA 0.00
- CRDL -0.02
- Stochastic Oscillator
- HURA 0.00
- CRDL 19.23
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.